June 17, 2026 · BriMindInvest Research Team · 13 min read
The highest current yield is often a trap. The real wealth-builder is dividend growth — companies that increase their payout consistently, doubling your income stream every 5–7 years. Here are the best dividend growth stocks for 2026, screened for payout sustainability, streak length, and business quality.
SCHD and VYM yields have been refreshed to current trailing-twelve-month figures (SCHD ~3.1%, VYM ~2.4%, both down from earlier-2026 levels as prices rose), and Coca-Cola's dividend increase streak is updated to 64 consecutive years following its 2026 raise.
Dividend growth investing focuses on companies GROWING their dividends rapidly — not necessarily those paying the highest dividend today. The insight is powerful: today's small yield becomes tomorrow's large income stream if the dividend CAGR is high enough. A 0.8% yield compounding at 18% annually doubles every 4 years. After a decade, that same share pays nearly 4× its original dividend.
The contrast with high-yield is stark. AT&T has offered a 6–7% yield for years — superficially attractive. But AT&T's dividend was flat for a decade, then cut in 2022 as the company struggled under debt from failed acquisitions. The total return over 10 years has been deeply negative. Meanwhile, Visa (V) paid just 0.8% yield in 2014 — but grew its dividend at ~18% CAGR. The income stream from that original Visa position now far exceeds what AT&T pays, and the stock itself has appreciated dramatically.
The math favors growth. A company with a 7% yield that never grows its dividend pays $700/year on a $10,000 investment — forever. A company with a 0.8% yield growing at 18% annually pays $80 in year 1, but $400 in year 10, and $2,000 in year 20. The crossover typically happens around year 8–10, after which the dividend growth investor earns more income and still owns a stock worth multiple times more.
Consider $10,000 invested in Visa (V) in 2014, when the yield was approximately 0.8% (annual dividend ~$0.48/share, stock ~$60). At an 18% dividend CAGR over 10 years, the annual dividend per share grows from $0.48 to roughly $2.50 — and the stock has appreciated ~5× in price. Your annual dividend income on the original $10,000 position: approximately $4,000/year by 2024. That is a 40% yield on your original cost basis.
Now contrast: $10,000 in AT&T in 2014 at a 7% yield = $700/year in income. By 2024, the dividend had been flat and then cut, paying closer to $550/year on the original investment. The stock itself fell ~60% over the decade. The "high yield" investor earned ~$6,000 in dividends over 10 years and lost ~$6,000 in capital — roughly break-even before inflation. The dividend growth investor earned an annualized total return exceeding 20%/year.
A Dividend Aristocrat is an S&P 500 company with 25+ consecutive years of dividend increases. There are approximately 66 such companies. A Dividend King has 50+ consecutive years of increases — roughly 50 companies achieve this. These streaks are not accidents; they require consistently growing earnings, disciplined capital allocation, and management teams that prioritize shareholders over multiple economic cycles.
The streak functions as a quality filter. To maintain a 40-year dividend increase streak, a company must generate free cash flow through recessions, competitive disruptions, and management changes. It must not have been reckless with debt, acquisitions, or share buybacks at the expense of the dividend. This forces a discipline that benefits shareholders. Note that MMM (3M) dropped from the Aristocrats list in 2023 due to an asbestos litigation settlement that strained its cash flow — demonstrating that even iconic companies can lose the streak.
| Ticker | Company | Streak | Category | Notable |
|---|---|---|---|---|
| PG | Procter & Gamble | 66 yrs | Dividend King | Consumer staples pricing power |
| KO | Coca-Cola | 64 yrs | Dividend King | Buffett's yield on cost ~50%+ |
| JNJ | Johnson & Johnson | 62 yrs | Dividend King | Healthcare diversification |
| AWR | American States Water | 70+ yrs | Longest streak | Record for longest streak |
| ABBV | AbbVie | 53 yrs | Dividend King | Via Abbott heritage |
| MCD | McDonald's | 49 yrs | Near King | Franchise + real estate model |
| MMM | 3M | Dropped 2023 | Former Aristocrat | Asbestos settlement caused cut |
Streak = consecutive years of dividend increases. 5-yr CAGR = annualised dividend per share growth over the past 5 years. Payout ratio based on trailing 12-month GAAP earnings.
| Ticker | Yield | 5yr CAGR | Payout % | Notes |
|---|---|---|---|---|
| MSFT | 0.7% | 10% | 25% | Low yield, high quality |
| AAPL | 0.5% | 5% | 15% | Growing from tiny base |
| V | 0.8% | 18% | 22% | Highest CAGR among large caps |
| MA | 0.6% | 19% | 20% | Neck-and-neck with Visa |
| LLY | 0.8% | 15% | 30% | GLP-1 boom driving FCF surge |
| HD | 2.4% | 13% | 55% | Higher yield with solid growth |
| UNH | 1.4% | 15% | 28% | Managed care cash machine |
| AVGO | 1.5% | 20% | 30% | AI chip tailwind |
| LOW | 2.0% | 22% | 35% | Highest 5yr CAGR in table |
| NKE | 1.8% | 12% | 40% | Recovery play; 22-yr streak |
AI scores from BriMindInvest composite model. Fwd P/E based on next-twelve-months consensus estimates.
| Ticker | AI Score | Yield | 5yr CAGR | Payout % | Increase Streak | Fwd P/E |
|---|---|---|---|---|---|---|
| MSFT | 87 | 0.72% | +11% | 25% | 22 yrs | 32x |
| AVGO | 84 | 1.6% | +15% | 30% | 13 yrs | 28x |
| V | 88 | 0.81% | +17% | 22% | 16 yrs | 27x |
| UNH | 78 | 1.8% | +14% | 28% | 15 yrs | 18x |
| ABBV | 76 | 3.9% | +8% | 60% | 53 yrs | 14x |
| HD | 80 | 2.5% | +11% | 55% | 15 yrs | 23x |
| LIN | 82 | 1.4% | +8% | 35% | 31 yrs | 26x |
| MCD | 75 | 2.4% | +9% | 60% | 49 yrs | 22x |
At a 15% dividend CAGR, a $1 dividend becomes $2 in 5 years and $4 in 10 years. Even a modest 8% CAGR doubles income every 9 years. This is why dividend growth beats high-yield for long-term total return.
Not all dividend growers are created equal. Sustainable dividend growth requires the intersection of several qualities:
For investors who prefer diversified exposure over individual stock picking, four ETFs cover the dividend growth universe well.
| Ticker | ETF Name | Exp Ratio | Yield | 5yr Return | Streak Filter | Strategy |
|---|---|---|---|---|---|---|
| DGRO | iShares Dividend Growth ETF | 0.08% | 2.1% | 11.2% | 5+ yrs | Dividend growth + quality screen; excludes top 10% highest yielders to avoid yield traps |
| SCHD | Schwab US Dividend Equity ETF | 0.06% | 3.1% | 11.8% | 10+ yrs | FCF/debt, ROE, yield, 5-yr CAGR screen; best dividend CAGR of any broad dividend ETF over 10 years |
| VIG | Vanguard Dividend Appreciation ETF | 0.06% | 1.8% | 10.5% | 10+ yrs | Largest dividend-growth AUM; market-cap weighted; broadest diversification; Nasdaq US Dividend Achievers Select Index |
| NOBL | ProShares S&P 500 Dividend Aristocrats | 0.35% | 2.3% | 9.8% | 25+ yrs | Aristocrats only; equal-weighted; highest quality filter but highest ER and more concentrated in staples/industrials |
SCHD has the strongest 10-year dividend CAGR of the group (~11%) due to its quality + growth screen. VIG has the largest AUM and broadest diversification. DGRO sits in between. NOBL is the strictest quality filter but has the highest expense ratio and tends to be overweight consumer staples and industrials.
Consider $10,000 invested in SCHD (dividend growth, ~3.5% yield, ~11% dividend CAGR) vs $10,000 in a high-yield fund like SDY or a corporate bond ETF yielding 5% flat. After 10 years:
The crossover happens around year 5–6, after which SCHD generates more annual income despite starting with a lower yield. SCHD's total return (price appreciation + dividends) has exceeded most high-yield funds over any rolling 10-year period.
The dividend growth universe has evolved significantly over the past decade. Technology now dominates the fastest-growing dividend payers — companies like MSFT, AAPL, V, and MA have low starting yields but extremely high growth rates. Healthcare (JNJ, UNH, ABT) offers a middle ground: moderate yield with reliable 12–15% CAGR. Consumer staples (PG, KO) are the traditional dividend growth heartland but have slowed as markets saturate.
Microsoft's dividend is funded by a diversified cash-generation machine spanning Azure cloud infrastructure, Office 365 subscriptions, and Windows/enterprise licensing — a mix that has kept free cash flow growing steadily even as the company plows tens of billions into AI data center capex.
A 25% payout ratio leaves enormous room to keep raising the dividend even if earnings growth slows, and Microsoft's Azure and Copilot AI products give it a second growth engine beyond its legacy software franchises. The 22-year increase streak reflects an unusually resilient, diversified cash flow base.
Massive AI data center capex is consuming a growing share of free cash flow, and if AI monetization (Copilot, Azure AI services) disappoints relative to the capital committed, that could slow the pace of future dividend increases even though an outright cut remains highly unlikely.
Broadcom sells the custom AI networking and accelerator chips that hyperscalers use to connect thousands of GPUs together, and has diversified into enterprise software (via its VMware acquisition) that generates high-margin, recurring licensing revenue.
Custom AI silicon for hyperscaler customers (Google's TPUs among them) gives Broadcom a second major AI revenue stream beyond networking chips, and the VMware integration is adding high-margin software revenue that supports continued double-digit dividend growth on top of a still-moderate 30% payout ratio.
Broadcom's largest customers are a small number of hyperscalers negotiating custom chip contracts — losing or renegotiating even one of these relationships could meaningfully dent growth. The stock's premium valuation assumes AI infrastructure spending keeps compounding at its current pace.
Visa operates the payment network that banks and merchants use to process card transactions, taking a small fee on nearly every swipe without needing to hold consumer credit risk — an asset-light toll-booth model that scales globally with minimal incremental capital.
The network's near-zero incremental capex means almost every dollar of revenue growth flows straight to free cash flow, funding a dividend that has compounded at 15-20% annually off a low starting yield. A 22% payout ratio leaves years of room to keep growing the dividend even in a slower economy.
Regulatory pressure on interchange fees (both in the US and internationally) is a recurring threat to Visa's take rate, and the long-term shift toward real-time bank-to-bank payment rails and stablecoins could eventually erode card network volume if adoption accelerates faster than expected.
UnitedHealth combines the largest US health insurance business with Optum, a fast-growing segment spanning pharmacy benefit management, data analytics, and physician practices — giving it cash flow diversified across both the insurance and healthcare-delivery sides of the industry.
Optum's growth has been diversifying UnitedHealth's earnings away from pure insurance underwriting risk, and a 28% payout ratio combined with a 15-year increase streak reflects a business that has historically compounded dividends at a pace that roughly doubles income every 5 years.
Medical cost trend and Medicare Advantage reimbursement policy are the two biggest swing factors for UnitedHealth's margins, and regulatory or political scrutiny of insurer practices (claims denials, PBM structure) has intensified — any adverse policy shift could pressure earnings growth and slow dividend increases.
AbbVie is a pharmaceutical company whose blockbuster immunology drug Humira lost patent exclusivity to biosimilar competition, but the company has successfully transitioned growth to newer drugs Skyrizi and Rinvoq, which are now larger combined franchises than Humira ever was at its peak.
The 53-year dividend increase streak (via its Abbott Laboratories lineage) makes AbbVie one of the longest-running Dividend Kings in the market, and Skyrizi/Rinvoq's continued share gains show the post-Humira transition has largely worked — giving confidence the streak can continue.
A 60% payout ratio is meaningfully higher than the other names on this list, leaving less cushion if drug pricing reform or new competitive entrants pressure Skyrizi/Rinvoq pricing power. Patent cliffs are a recurring structural risk for any pharma company, and AbbVie will eventually face one for its current lead drugs too.
Home Depot is the largest home improvement retailer in the US, serving both DIY consumers and professional contractors — a mix it has been expanding through the SRS Distribution acquisition, which deepens its reach into the professional/trade contractor market.
SRS Distribution integration is expanding Home Depot's addressable market into the professional contractor segment, which tends to be stickier and less discretionary than DIY consumer spending. A housing market recovery (lower rates unlocking existing-home turnover) would be a meaningful tailwind for both new-construction and renovation-related sales.
Home Depot's sales are cyclically tied to housing turnover and consumer discretionary spending — a prolonged period of high mortgage rates suppressing existing-home sales would weigh on big-ticket renovation spending, and a 55% payout ratio is on the higher end of this group, leaving less room for error in a downturn.
Linde produces and delivers industrial gases (oxygen, nitrogen, hydrogen) that chemical plants, steel mills, hospitals, and semiconductor fabs need to operate, typically under long-term take-or-pay contracts that guarantee minimum revenue regardless of how much gas the customer actually uses.
Take-or-pay contract structures and on-site production facilities built next to customer plants create near-monopoly economics in each local market — a competitor would need to build a duplicate plant next door to compete, which rarely pencils out. This gives Linde unusually predictable, contracted cash flow to support its 31-year dividend increase streak.
Linde's growth is tied to industrial production and capital spending cycles in the chemical, steel, and semiconductor industries it serves — a global manufacturing slowdown would reduce demand for new on-site gas contracts, even if existing take-or-pay contracts continue to be honored.
McDonald's operates primarily as a real estate and franchise royalty business rather than a traditional restaurant operator — it owns or leases the land under most locations and collects rent plus a royalty on franchisee sales, producing highly predictable, high-margin cash flow that's less exposed to individual restaurant labor and food costs.
The franchise/real estate model means McDonald's earnings are largely insulated from restaurant-level cost inflation, and AI-driven drive-through ordering and kitchen automation are incrementally improving franchisee margins, which supports royalty growth. A 49-year increase streak puts it one year from Dividend King status.
A 60% payout ratio limits flexibility, and McDonald's same-store sales growth has been slowing in a value-conscious consumer environment, with discount-driven competition from other fast-food chains pressuring traffic. Any prolonged consumer pullback on discretionary dining would directly hit royalty revenue.
Quality-filtered selection based on FCF/debt, ROE, yield, and 5-yr dividend growth; strongest dividend CAGR of any broad dividend ETF
Broader diversification; market-cap weighted; higher starting yield but lower growth rate than SCHD over most periods
Dividend growth investing is one of the most evidence-backed strategies in equity investing. The key insight is counterintuitive: the lowest-yielding companies with the fastest dividend growth often produce the highest total returns over 10+ years. Visa's 0.8% yield growing at 18%/year beats AT&T's 7% yield flat over any meaningful time horizon — both on income and on total return.
For 2026, the strongest dividend growth candidates are concentrated in technology (MSFT, V, MA, AVGO), healthcare (UNH, LLY), and select retail (HD, LOW). These stocks offer modest starting yields but dividend CAGRs of 10–22% that compound dramatically over time. Pair individual names with SCHD or DGRO for ETF exposure, and focus on low payout ratios, high FCF, and pricing power as the primary sustainability filters.
For investors who want income now, SCHD at 3.1% yield with 11% dividend CAGR is arguably the best single position available — it provides meaningful current income while growing that income at more than double the rate of inflation.
Get AI prediction signals, unlimited stock comparisons, portfolio analytics, and personalized watchlists — free for 14 days, no credit card required.
14-day free trial · No credit card required · Cancel anytime
Not ready to sign up? Get one free email a week instead.